Farxiga Tablet, Film Coated
Product Images NDC 50090-3482

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 50090-3482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
This is a table showing the number of patients who had an event and the number of patients at risk for a clinical trial involving FARXIGA and placebo. The table lists the months from randomization and the patient count for each month.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
FDA Label Image

Figure 6a (Figure 6a)

Figure 6a (Figure 6a)
This is a clinical study result for the drug FARXIGA compared to a Placebo for the treatment of an undisclosed condition. The study followed patients for 24 months and shows a reduction in the occurrence of the event in the group taking FARXIGA compared to the Placebo group.*
FDA Label Image

Figure 6b (Figure 6b)

Figure 6b (Figure 6b)
This is a clinical trial comparison between the drug FARXIGA and a placebo. The graph displays the percentage of patients with a medical event over a two-year period starting from randomization. Patients taking FARXIGA had a lower rate of medical events - the hazard ratio was 0.82 (with a 95% confidence interval of 0.69 to 0.98) and a P-value of 0.0294. The number of patients at risk over the 24 months is shown for both treatment groups.*
FDA Label Image

Figure 6c (Figure 6c)

Figure 6c (Figure 6c)
This text appears to be a comparison of the effectiveness of the drug FARXIGA versus a placebo, with data on the number of patients with an event (%) over a period of 24 months, along with hazard ratios and p-values. The data is presented in a table format with patients at risk for each month.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
FDA Label Image

Figure 1 (Farxiga Fig1)

Figure 1 (Farxiga Fig1)
This appears to be a graph that shows the correlation between the dosage of a medication called Dapagiiizin and the amount of glucose present in the urine of study participants. There are two separate groups represented on the graph: healthy subjects and those with a condition abbreviated to "T20M". The graph includes two fitted lines to represent the correlation between dosage and glucose levels for these groups.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
This is a statistical report showing a comparison between Farxiga and a Placebo. It includes data on the number of patients with an event, percentage, Hazard Ratio, P-value, and patients at risk. The report also includes a chart with months from randomization and patients at risk over time.*
FDA Label Image

Farxiga Figure 2 (Image 01)

Farxiga Figure 2 (Image 01)
FDA Label Image

Farxiga Figure 3 (Image 02)

Farxiga Figure 3 (Image 02)
This is a graph showing the adjusted mean change from baseline HbA1c levels over time in a study with randomized subjects who completed a short-term period without rescue. The graph includes two lines, one for the placebo plus metformin group and the other for the Farxiga 10 mg plus metformin group. The graph also includes error bars and study week intervals. The text also includes a description of the statistical models used to generate the data.*
FDA Label Image

Label Image (Lbl500903481)

Label Image (Lbl500903481)
This is a medication product description for Dapagliflozin 16mg tablets. The recommended storage for the tablets is at 68-77 degrees Fahrenheit. The product code is EI57-0 and the package includes 30 tablets.*
FDA Label Image

Label Image (Lbl500903482)

Label Image (Lbl500903482)
Product No. 6796-0 is a product identified as "LoT' FARKIGA" which contains the active ingredient Dapagliflozin. Further information about the product is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.